ID
17655
Description
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Keywords
Versions (2)
- 8/1/16 8/1/16 -
- 9/27/16 9/27/16 -
Uploaded on
September 27, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Prevention and Treatment of Skin, Hair and Nail Reactions, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Description
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration
Description
Record all topical creams, gels, oral or IV medications, and/or other interventions used to prevent and treat skin, hair and nail reactions (includes rash, skin fissures, nail and hair changes, etc) due to study drug administration. Moisturizers and sunscreens used to prevent and treat skin reactions should be recorded on the Moisturizers and Sunscreens CRF page.
Data type
text
Alias
- UMLS CUI [1,1]
- C0087111
- UMLS CUI [1,2]
- C0221743
- UMLS CUI [2,1]
- C0087111
- UMLS CUI [2,2]
- C0018500
- UMLS CUI [3,1]
- C0087111
- UMLS CUI [3,2]
- C0234909
Description
Indication Prophylaxis
Data type
boolean
Alias
- UMLS CUI [1,1]
- C3146298
- UMLS CUI [1,2]
- C0199176
Description
Drug Administration Route
Data type
integer
Alias
- UMLS CUI [1]
- C0013153
Description
Drug Administration Route
Data type
text
Alias
- UMLS CUI [1]
- C0013153
Description
Specific Indication should be reported on the Adverse Event (Including Baseline Signs/Symptoms) CRF page, unless the intervention was given as a prophylaxis.
Data type
integer
Alias
- UMLS CUI [1]
- C3146298
Description
Indication
Data type
text
Alias
- UMLS CUI [1]
- C3146298
Description
Date Started
Data type
date
Alias
- UMLS CUI [1]
- C3173309
Description
Date Stopped
Data type
date
Alias
- UMLS CUI [1]
- C1531784
Description
Date Stopped
Data type
boolean
Alias
- UMLS CUI [1]
- C1531784
Similar models
Prevention and Treatment of Skin, Hair and Nail Reactions Due to Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C0221743 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018500 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0234909 (UMLS CUI [3,2])
C0221743 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0018500 (UMLS CUI [2,2])
C0087111 (UMLS CUI [3,1])
C0234909 (UMLS CUI [3,2])
C0199176 (UMLS CUI [1,2])